Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103


Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?

Viana PCC, Horvat N, do Santos VR Júnior, Lima TC, Romão DDS, Cerri LMO, de Castro MG, Vargas HA, Miranda JA, Leite CDC, Cerri GG.

Int Braz J Urol. 2019 Jul-Aug;45(4):724-731. doi: 10.1590/S1677-5538.IBJU.2018.0382.


Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.

Schaudinn A, Gawlitza J, Mucha S, Linder N, Franz T, Horn LC, Kahn T, Busse H.

Eur J Radiol. 2019 Jul;116:180-185. doi: 10.1016/j.ejrad.2019.04.012. Epub 2019 May 14.


[Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].

Zuo MZ, Zhao WL, Wei CG, Zhang CY, Wen R, Gu YF, Li MJ, Zhang YY, Wu JF, Li X, Shen JK.

Zhonghua Yi Xue Za Zhi. 2017 Dec 19;97(47):3693-3698. doi: 10.3760/cma.j.issn.0376-2491.2017.47.003. Chinese.


Head-to-head comparison of PI-RADS v2 and PI-RADS v1.

Polanec S, Helbich TH, Bickel H, Pinker-Domenig K, Georg D, Shariat SF, Aulitzky W, Susani M, Baltzer PA.

Eur J Radiol. 2016 Jun;85(6):1125-31. doi: 10.1016/j.ejrad.2016.03.025. Epub 2016 Mar 29.


Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.

Tewes S, Hueper K, Hartung D, Imkamp F, Herrmann TR, Weidemann J, Renckly S, Kuczyk MA, Wacker F, Peters I.

World J Urol. 2015 Nov;33(11):1707-14. doi: 10.1007/s00345-015-1525-4. Epub 2015 Mar 14.


Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.

Feng ZY, Wang L, Min XD, Wang SG, Wang GP, Cai J.

Chin Med J (Engl). 2016 Oct 20;129(20):2451-2459. doi: 10.4103/0366-6999.191771.


Evaluating the performance of PI-RADS v2 in the non-academic setting.

Jordan EJ, Fiske C, Zagoria RJ, Westphalen AC.

Abdom Radiol (NY). 2017 Nov;42(11):2725-2731. doi: 10.1007/s00261-017-1169-5.


Accuracy of multiparametric MR imaging with PI-RADS V2 assessment in detecting infiltration of the neurovascular bundles prior to prostatectomy.

Sauer M, Weinrich JM, Fraune C, Salomon G, Tennstedt P, Adam G, Beyersdorff D.

Eur J Radiol. 2018 Jan;98:187-192. doi: 10.1016/j.ejrad.2017.11.019. Epub 2017 Nov 27.


Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.

Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, Miyagawa T.

BJU Int. 2017 Feb;119(2):225-233. doi: 10.1111/bju.13465. Epub 2016 Apr 1.


Diagnostic Performance and Interobserver Consistency of the Prostate Imaging Reporting and Data System Version 2: A Study on Six Prostate Radiologists with Different Experiences from Half a Year to 17 Years.

Ke Z, Wang L, Min XD, Feng ZY, Kang Z, Zhang PP, Li BS, You HJ, Hou SC.

Chin Med J (Engl). 2018 Jul 20;131(14):1666-1673. doi: 10.4103/0366-6999.235872.


Multiparametric magnetic resonance imaging - Transrectal ultrasound-guided cognitive fusion biopsy of the prostate: Clinically significant cancer detection rates stratified by the Prostate Imaging and Data Reporting System version 2 assessment category.

John S, Cooper S, Breau RH, Flood TA, Cagiannos I, Lavallee LT, Morash C, O'sullivan J, Schieda N.

Can Urol Assoc J. 2018 Jun 19. doi: 10.5489/cuaj.5254. [Epub ahead of print]


The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer.

Zhao C, Gao G, Fang D, Li F, Yang X, Wang H, He Q, Wang X.

Clin Imaging. 2016 Sep-Oct;40(5):885-8. doi: 10.1016/j.clinimag.2016.04.010. Epub 2016 Apr 26.


Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J.

Eur Urol. 2019 Mar;75(3):385-396. doi: 10.1016/j.eururo.2018.05.035. Epub 2018 Jun 13.


Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.

Alessi S, Pricolo P, Summers P, Femia M, Tagliabue E, Renne G, Bianchi R, Musi G, De Cobelli O, Jereczek-Fossa BA, Bellomi M, Petralia G.

Eur Radiol. 2019 Mar 18. doi: 10.1007/s00330-019-06092-0. [Epub ahead of print]


Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.

Ullrich T, Arsov C, Quentin M, Laqua N, Klingebiel M, Martin O, Hiester A, Blondin D, Rabenalt R, Albers P, Antoch G, Schimmöller L.

Eur J Radiol. 2019 Apr;113:1-6. doi: 10.1016/j.ejrad.2019.01.030. Epub 2019 Feb 1.


Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?

Hoffmann R, Logan C, O'Callaghan M, Gormly K, Chan K, Foreman D.

Int Urol Nephrol. 2018 Jan;50(1):13-19. doi: 10.1007/s11255-017-1753-1. Epub 2017 Nov 29.


The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.

Wang X, Bao J, Ping X, Hu C, Hou J, Dong F, Guo L.

Oncol Lett. 2018 Sep;16(3):3201-3206. doi: 10.3892/ol.2018.9038. Epub 2018 Jun 28.


Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer.

Dola EF, Nakhla OL, Genidi EA.

Eur J Radiol Open. 2017 Mar 21;4:19-26. doi: 10.1016/j.ejro.2017.02.001. eCollection 2017.


The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.

Cao Y, Cao M, Chen Y, Yu W, Fan Y, Liu Q, Gao G, Zhao Z, Wang X, Jin J.

Oncotarget. 2017 Jul 4;8(27):44040-44049. doi: 10.18632/oncotarget.17182.

Supplemental Content

Support Center